title: Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization.
abstract: OBJECTIVE
  Discovery transcriptomic analyses suggest eukaryotic initiation factor 3b (eIF3b) is elevated in human bladder and prostate cancer, yet its role as a prognostic factor or its requirement in the maintenance or progression of human cancer is not established. Here, we determine the therapeutic potential of eIF3b by examining the clinical relevance of its expression in human cancer tissues and its role in experimental tumor models.
  
  
  METHODS
  We examined mRNA expression of eIF3b in bladder (N = 317) and prostate (N = 566) tissue samples and protein expression by immunohistochemistry in 143 bladder tumor samples as a function of clinicopathologic features. The impact of eIF3b depletion by siRNA in human cancer lines was evaluated in regard to in vitro cell growth, cell cycle, migration, in vivo subcutaneous tumor growth, and lung colonization.
  
  
  RESULTS
  eIF3b mRNA expression correlated to tumor grade, stage, and survival in human bladder and prostate cancer. eIF3b protein expression stratified survival in human bladder cancer. eIF3b depletion reduced in vitro cancer cell growth; inhibited G1-S cell-cycle transition by changing protein but not RNA expression of cyclin A, E, Rb, and p27Kip1; inhibited migration; and disrupted actin cytoskeleton and focal adhesions. These changes were associated with decreased protein expression of integrin α5. Integrin α5 depletion phenocopied effects observed with eIF3b. eIF3b-depleted bladder cancer cells formed fewer subcutaneous tumors that grew more slowly and had reduced lung colonization.
  
  
  CONCLUSIONS
  eIF3b expression relates to human bladder and prostate cancer prognosis, is required for tumor growth, and thus a candidate therapeutic target.
authors.affiliation: Department of Surgery (Urology), University of Colorado, Aurora, Colorado 80045, USA.
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.forename: Yuanbin
authors.initials: Y
authors.lastname: Ru
authors.forename: Marta
authors.initials: M
authors.lastname: Sanchez-Carbayo
authors.forename: Xuejiao
authors.initials: X
authors.lastname: Wang
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Kieft
authors.forename: Dan
authors.initials: D
authors.lastname: Theodorescu
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D002453:Cell Cycle / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D018450:Disease Progression; D039621:Eukaryotic Initiation Factor-3 / Q000235:genetics* / Q000378:metabolism; D005260:Female; D022001:Focal Adhesions / Q000235:genetics; D015870:Gene Expression; D020869:Gene Expression Profiling; D064593:Heterografts; D006801:Humans; D039482:Integrin alpha5 / Q000235:genetics / Q000378:metabolism; D008175:Lung Neoplasms / Q000556:secondary*; D008297:Male; D051379:Mice; D009369:Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D010641:Phenotype; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology; D014176:Protein Biosynthesis / Q000235:genetics; D047368:Tumor Burden / Q000235:genetics; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000473:pathology
chemical_list: D000199:Actins; D039621:Eukaryotic Initiation Factor-3; D039482:Integrin alpha5